Effect of Resvega in a model of choroidal neovascularization in mice

Abstract

AbstractPurpose We aim to assess the effect of Resvega as a source of resveratrol and combined with an anti‐VEGF in a diode laser‐induced choroidal neovascularization (Li‐CNV) model in mice.Methods Sixty C57BL6/J mice underwent a diode Li‐CNV model, and were divided into 4 groups (n=15): Control group: vehicle by oral gavage. NA group: daily oral Resvega (NA). C‐VEGF group: vehicle and intravitreal anti‐VEGF. NA‐VEGF group: NA and intravitreal anti‐VEGF. Oral treatments (100 µL) were administered 10 days before laser until 28 days post‐laser. Intravitreal injections (7 µl) were performed 48 hours after laser. CNV evolution was assessed weekly through fluorescein angiography (FA) for 4 weeks. CD‐31 immunofluorescence was assessed in choroidal flat mounts after sacrifice. Gene and protein expression of VEGF was analyzed with RT‐PCR and western‐blot, respectively. Results were analyzed with SPSS 15.0.Results FA showed a significant decrease in fluorescein leakage from second week in NA and NA‐VEGF groups compared with their respective controls (p<0.05). The lowest CNV area measured by CD31 was observed in NA group compared with control group with statistically significant differences (p<0.05). RT‐PCR and western‐blot analysis showed a significant decrease in VEGF expression in NA and NA‐VEGF groups (p<0.05).Conclusion Our data show that oral Resvega administration reduces CNV area and expression of proangiogenic VEGF expression. These results suggest that Resvega could be considered as potential preventive therapy against CNV. Supported in part by Thea Laboratoires and Grant RETICS RD 07/0062, Ministerio de Ciencia e Innovación.